Richard K. Burt, M.D.

Division Chief

Division of Immunotherapy
Department of Medicine
446 E. Ontario Street Suite 10-1000
Chicago, IL 60611
Tel (312) 695-4960
Fax (312) 695-4961

Thank you for your interest in our study for treating relapsing remitting multiple sclerosis.
Inclusion Criteria:
1.

Age between 18-55

2.

Confirmed diagnosis of MS (using McDonald criteria)

3.

EDSS of 2.0-6.0 (and confirmed by our study neurologist)

4.

Failure to respond to minimum of 6 months of standard of care treatment (such as interferon,

Copaxone, tecfidera, Tysabri, etc)

5.

Active Inflammatory disease defined as follows: TWO or more incidents in past 12 months
compatible with inflammatory disease. This includes MRI with enhancing lesion in past 12
months AND/OR acute attack documented by neurologist and treated with high dose steroids.

Exclusion criteria:
1.

Any illness that would jeopardize your ability to tolerate aggressive chemotherapy.

2.

History of cancer (except certain cancers which the patient is judged to be cured)

3.

Positive pregnancy test.

4.

Inability or unwillingness to pursue effective means of birth control.

5.

Failure to willingly accept or comprehend irreversible sterility as a side effect of therapy.

6.

Decreased lung function evaluated by pulmonary function test

7.

Echo or MUGA with Resting LVEF < 50 %.

8.

Liver impairment: Bilirubin > 2.0 mg/dl.

9.

Impaired kidney function: Serum creatinine > 2.0 mg/dl.

10. Known hypersensitivity to mouse, rabbit, or E. Coli derived proteins, or to iron

compounds/medications.
11. Presence of metallic objects implanted in the body that would preclude the ability to have MRI
exams.
12. Diagnosis of primary progressive MS.
13. Diagnosis of secondary progressive MS
14. Platelet count < 100,000/ul, WBC < 1,500 cells/mm3.
15. Psychiatric illness, mental deficiency or cognitive dysfunction making compliance with
treatment or informed consent impossible.
16. Active infection.
17. Use of Tysabri in past 6 months
18. Use of Aubagio (Teriflunomide) within the past 2 years unless cleared from body following
elimination protocol with cholestyramine- confirmed by laboratory test
19. Prior treatment of CAMPATH
20. Prior treatment with Mitoxantrone